Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 14/20 | 0.40 |
| ▸ | DBF4 | Q9UBU7 | 14/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 13/20 | 0.39 |
| ▸ | CCNE1 | P24864 | 12/20 | 0.38 |
| ▸ | CDK2 | P24941 | 12/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21729515 | 0.87 | AAK1 (0.37) | CDC7DBF4ROCK1CCNE1CDK2 | |
| SCHEMBL21712637 | 0.84 | CDC7 (0.47) | CDC7DBF4ROCK1CCNE1CDK2 | |
| SCHEMBL21712628 | 0.82 | CDC7 (0.47) | CDC7DBF4ROCK1CCNE1CDK2 | |
| SCHEMBL20572270 | 0.82 | CDC7 (0.42) | CDC7DBF4ROCK1CCNE1CDK2 | |
| SCHEMBL21712608 | 0.81 | CDC7 (0.42) | CDC7DBF4ROCK1CCNE1CDK2 | |
| SCHEMBL21712611 | 0.81 | CDC7 (0.42) | CDC7DBF4ROCK1CCNE1CDK2 | |
| SCHEMBL21712591 | 0.80 | CDC7 (0.46) | CDC7DBF4ROCK1CCNE1CDK2 | |
| Hydrochloric Acid SCHEMBL21712613 | 0.80 | CDC7 (0.41) | CDC7DBF4ROCK1CCNE1CDK2 | |
| Hydrochloric Acid SCHEMBL21712616 | 0.80 | CDC7 (0.41) | CDC7DBF4ROCK1CCNE1CDK2 | |
| SCHEMBL21712595 | 0.79 | KMT2A (0.39) | CDC7DBF4ROCK1CCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10745410-B2 | Substituted [5,6]cyclic-4(3H)-pyrimidinones as anticancer agents | ZENJI RESEARCH LABORATORIES (CN) | 2020-08-18 | — | — | US | disclosed |
| US-20200055867-A1 | SUBSTITUTED [5,6]CYCLIC-4(3H)-PYRIMIDINONES AS ANTICANCER AGENTS | ZENJI RESEARCH LABORATORIES (CN) | 2020-02-20 | — | — | US | disclosed |
| WO-2018217439-A1 | SUBSTITUTED [5,6]CYCLIC-4(3H)-PYRIMIDINONES AS ANTICANCER AGENTS | ZHANG HAI JUN (US) | 2018-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200055867-A1 | SUBSTITUTED [5,6]CYCLIC-4(3H)-PYRIMIDINONES AS ANTICANCER AGENTS | CDC7, CDK7, CDK17 | CDC7 1/4885DBF4 1421/4885ROCK1 1409/4885 |
| US-10745410-B2 | Substituted [5,6]cyclic-4(3H)-pyrimidinones as anticancer agents | CDC7, CDK7, CDK17 | CDC7 1/4885DBF4 1421/4885ROCK1 1409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.